US FDA Wants Remote Regulatory Assessment Authority For Cosmetics – FY 2023 Budget Justification
Executive Summary
After freezing its routine inspection activities at the height of the COVID-19 pandemic, the FDA adapted its oversight approach visibly in the drug and medical devices sectors, including with voluntary remote regulatory assessments. The agency now seeks authority to continue that work on a non-voluntary basis across all FDA-regulated programs.